CA3024153A1 - Procedes de preparation d'oligomeres morpholino de phosphorodiamidate - Google Patents

Procedes de preparation d'oligomeres morpholino de phosphorodiamidate Download PDF

Info

Publication number
CA3024153A1
CA3024153A1 CA3024153A CA3024153A CA3024153A1 CA 3024153 A1 CA3024153 A1 CA 3024153A1 CA 3024153 A CA3024153 A CA 3024153A CA 3024153 A CA3024153 A CA 3024153A CA 3024153 A1 CA3024153 A1 CA 3024153A1
Authority
CA
Canada
Prior art keywords
formula
compound
group
support
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024153A
Other languages
English (en)
Inventor
Bao Cai
Mitchell MARTINI
Katie THOMAS
Ross SHIMABUKU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CA3024153A1 publication Critical patent/CA3024153A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

L'invention concerne des procédés de préparation d'un oligomère (par exemple, un oligomère morpholino). Les procédés de synthèse décrits dans l'invention peuvent être avantageux pour la mise à l'échelle de la synthèse d'oligomères tout en maintenant le rendement global et la pureté d'un oligomère synthétisé.
CA3024153A 2016-06-30 2017-06-30 Procedes de preparation d'oligomeres morpholino de phosphorodiamidate Pending CA3024153A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662357134P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US62/357,134 2016-06-30
US62/357,153 2016-06-30
US201762508256P 2017-05-18 2017-05-18
US62/508,256 2017-05-18
PCT/US2017/040311 WO2017205879A2 (fr) 2016-05-24 2017-06-30 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Publications (1)

Publication Number Publication Date
CA3024153A1 true CA3024153A1 (fr) 2017-11-30

Family

ID=64425889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024153A Pending CA3024153A1 (fr) 2016-06-30 2017-06-30 Procedes de preparation d'oligomeres morpholino de phosphorodiamidate

Country Status (10)

Country Link
EP (1) EP3463389A4 (fr)
JP (1) JP7022079B2 (fr)
KR (1) KR102523522B1 (fr)
CN (1) CN109152792B (fr)
AU (1) AU2017270598B2 (fr)
CA (1) CA3024153A1 (fr)
CO (1) CO2018013831A2 (fr)
MX (1) MX2018014160A (fr)
SG (1) SG11201809502YA (fr)
WO (1) WO2017205879A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP7022078B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
EP3657604A1 (fr) 2018-11-26 2020-05-27 TE Connectivity Germany GmbH Ensemble de terminaison de câble avec des lames de coupe électriquement isolantes
EP4230196A1 (fr) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Composés à utiliser dans le traitement des dystrophinopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
CA1339987C (fr) 1988-09-01 1998-08-04 Robert Bruce Merrifield Methode pour la synthese de peptides; support solide utile a cette fin
KR100386542B1 (ko) * 1993-12-29 2003-10-11 후지사와 야꾸힝 고교 가부시키가이샤 피라졸로피리딘아데노신길항제
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2884340C (fr) 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Procede de synthese d'oligomeres morpholino
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
CA2799501C (fr) * 2010-05-28 2022-02-15 Sarepta Therapeutics, Inc. Analogues oligonucleotidiques ayant des liaisons modifiees entre sous-unites et/ou des groupes terminaux modifies
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
KR102183273B1 (ko) * 2011-05-05 2020-11-27 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
AU2012345638C1 (en) * 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN110066793A (zh) * 2013-03-14 2019-07-30 萨勒普塔医疗公司 用于治疗肌肉萎缩的外显子跳跃组合物
BR122020016865B1 (pt) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
CN105228999B (zh) * 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
BR122022014984B1 (pt) * 2016-05-24 2024-03-05 Sarepta Therapeutics, Inc Compostos oligômeros morfolino fosforodiamidato
AU2017271524B2 (en) 2016-05-24 2021-06-24 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
JP7022078B2 (ja) 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
MA45618A (fr) 2016-06-30 2019-05-08 Sarepta Therapeutics Inc Sauts d'exons oligomères pour la dystrophie musculaire

Also Published As

Publication number Publication date
CO2018013831A2 (es) 2018-12-28
EP3463389A4 (fr) 2020-02-19
CN109152792B (zh) 2021-09-14
KR20190020674A (ko) 2019-03-04
EP3463389A2 (fr) 2019-04-10
JP7022079B2 (ja) 2022-02-17
KR102523522B1 (ko) 2023-04-20
WO2017205879A2 (fr) 2017-11-30
CN109152792A (zh) 2019-01-04
JP2019518748A (ja) 2019-07-04
AU2017270598B2 (en) 2022-12-01
WO2017205879A3 (fr) 2018-01-18
SG11201809502YA (en) 2018-12-28
AU2017270598A1 (en) 2019-01-17
MX2018014160A (es) 2019-04-01

Similar Documents

Publication Publication Date Title
EP3464306B1 (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
AU2017270975B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
US11384105B2 (en) Processes for preparing oligomers
US20220112491A1 (en) Processes for preparing phosphorodiamidate morpholino oligomers
CA3024153A1 (fr) Procedes de preparation d'oligomeres morpholino de phosphorodiamidate
US11472824B2 (en) Processes for preparing phosphorodiamidate morpholino oligomers
CN109152775B (zh) 制备磷酸二酰胺吗啉代寡聚物的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623